Kabir Yousuf, MD
Cardiovascular Disease · Fleming Island, FLNPI 1174595763
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 14.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,046 and has fallen 63.8% since, to $379 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in FL, where the typical reported total is $2,774.
Across 72 payments — averaging $32.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$346
- Novartis$222
- Medtronic$201
- Amgen$199
- Baxter Healthcare$172
- Pfizer$166
- plus $1K from 16 others
Across 1,049 payments — averaging $1605.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1.2M
- Novartis$128K
- Boehringer Ingelheim International GmbH$108K
- Merck$101K
- Pfizer$74K
- Amgen$37K
- plus $78K from 3 others
What the payments were for
- Food & beverage$2,31699%
- Education$141%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 4 | $346 |
| Novartis | 12 | $222 |
| Medtronic | 2 | $201 |
| Amgen | 6 | $199 |
| Baxter Healthcare | 3 | $172 |
| Pfizer | 8 | $166 |
| Boston Scientific | 2 | $140 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $126 |
| Siemens Medical Solutions USA, Inc. | 1 | $125 |
| Shockwave Medical, Inc | 1 | $124 |
| Johnson & Johnson | 12 | $114 |
| Edwards Lifesciences | 1 | $109 |
| E.r. Squibb & Sons, L.L.C. | 4 | $63 |
| GE HealthCare | 1 | $59 |
| Cvrx, Inc. | 2 | $39 |
| AstraZeneca | 2 | $28 |
| Boehringer Ingelheim | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Gilead | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,330 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 117 | $117,344 |
| EntrestoSacubitril/Valsartan | 41 | $43,167 |
| Repatha SureclickEvolocumab | 39 | $36,533 |
| XareltoRivaroxaban | 20 | $27,078 |
| JardianceEmpagliflozin | 15 | $17,709 |
| Praluent PenAlirocumab | 27 | $13,650 |
| BrilintaTicagrelor | 12 | $8,794 |
| Amiodarone Hcl | 43 | $2,923 |
| Metoprolol Succinate | 175 | $1,990 |
| Ezetimibe | 21 | $1,249 |
| Atorvastatin Calcium | 152 | $908 |
| Losartan Potassium | 102 | $703 |
| Valsartan | 34 | $689 |
| Amlodipine Besylate | 125 | $627 |
| Nifedipine ErNifedipine | 41 | $591 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $166 | $117,344117 claims |
| NovartisEntresto | $222 | $43,16741 claims |
| Johnson & JohnsonXarelto | $114 | $27,07820 claims |
| Boehringer IngelheimJardiance | $24 | $17,70915 claims |
| AstraZenecaBrilinta | $28 | $8,79412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,740 cardiovascular disease providers in Florida.
Other cardiovascular disease in Fleming Island
- Carlos ZamoraFleming Island$110K
- Kevin MakatiLutz$1.6M
- Hiram BezerraTampa$698K
- William OneillNaples$637K
- Theodore FeldmanMiami$637K
- John Gerald CantoLakeland$588K
- Alan MillerJacksonville$547K
- Seth BaumBoca Raton$517K
- Elliott EliasMiami$497K
- Vijay HaryaniVero Beach$413K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.